Overview

Bioequivalence Study of Rivaroxaban

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 15 mg and rivaroxaban granule formulation 15 mg, and to assess the safety and tolerability of rivaroxaban 15 mg in healthy adult male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Rivaroxaban